Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions

2024-10-1

BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

2024-10-1

Early versus late response to PD-1-based immunotherapy in metastatic melanoma

2024-10-1

PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors

2024-10-1

The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: a retrospective cohort study

2024-10-1

Assessing actionability and incidental findings of germline variants in two precision oncology trials

2024-10-1

5-Hydroxymethylcytosines in circulating cell-free DNA as a diagnostic biomarker for nasopharyngeal carcinoma

2024-10-1

Editorial Board

2024-9-18

Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study

2024-9-12

Letter Re: PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors

2024-9-1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population

2024-9-1

Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients

2024-9-1

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: a real-world study including 3,922 patients from the French REALYSA cohort

2024-9-1

Comparing supplemental indications for cancer drugs approved in the US and EU

2024-9-1

Capmatinib Plus Nazartinib in Patients With EGFR-Mutated Non–Small Cell Lung Cancer

2024-9-1

Integrated Nomogram to Predict HER2 Expression in Breast tumor: Clinical, Ultrasound, and Photoacoustic Imaging Approaches

2024-9-1

Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]

2024-9-1

The Role of CDCA2 in Tumor Genesis, Prognosis and Future Treatments

2024-9-1

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

2024-9-1

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)

2024-9-1

Adjustment for Imbalances in Baseline Characteristics in the MAGNITUDE Phase 3 Study Confirms the Clinical Benefit of Niraparib in Combination with Abiraterone Acetate Plus Prednisone in Patients with Metastatic Prostate Cancer

2024-9-1

Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021)

2024-9-1

The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study

2024-9-1

Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART

2024-9-1

Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice

2024-9-1

TNM 8 staging system beyond p16: double HPV/p16 status is superior to p16 alone in predicting outcome in oropharyngeal squamous cell carcinoma

2024-9-1

“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools

2024-9-1

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

2024-9-1

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

2024-9-1

Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma

2024-9-1

Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco Cluster-Randomized Controlled Trial

2024-9-1

Editorial Board

2024-9-1

Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months

2024-9-1

Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review

2024-9-1

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

2024-9-1

Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies

2024-9-1

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data

2024-9-1

Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on Head & Neck, Colorectal, and Breast cancers

2024-9-1

Protecting Cancer Survivors from Financial Discrimination throughout the EU: A cross-European Perspective

2024-9-1

HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome

2024-9-1

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study

2024-9-1

Treating cancer-associated venous thromboembolism: a practical approach

2024-9-1

An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations

2024-9-1

Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors

2024-9-1

Benchmarking Whole Exome Sequencing in the German Network for Personalized Medicine

2024-9-1

Germline Pathogenic Variants of Cancer Predisposition Genes in a multicentre Italian cohort of Pancreatic Cancer patients

2024-9-1

Empowering effective biomarker-driven precision oncology: A call to action

2024-9-1

Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?

2024-9-1

Editorial Board

2024-8-22

Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials

2024-8-22